Solomon Moshkevich Sells 6,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total value of $859,740.00. Following the sale, the insider now owns 143,768 shares of the company’s stock, valued at approximately $20,600,516.72. This trade represents a 4.01 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Wednesday, January 29th, Solomon Moshkevich sold 5,201 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $862,689.87.
• On Wednesday, January 22nd, Solomon Moshkevich sold 24,861 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,101,319.17.
• On Monday, December 9th, Solomon Moshkevich sold 4,858 shares of Natera stock. The stock was sold at an average price of $166.59, for a total value of $809,294.22.

Natera Trading Down 0.6 %

Natera stock opened at $140.66 on Friday. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The business’s fifty day simple moving average is $165.61 and its two-hundred day simple moving average is $147.70. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market capitalization of $19.02 billion, a price-to-earnings ratio of -79.92 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. The firm had revenue of $476.10 million for the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, equities analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NTRA shares. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. JPMorgan Chase & Co. lifted their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Sanford C. Bernstein lifted their price target on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. Piper Sandler lifted their price target on Natera from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 4th. Finally, Craig Hallum lifted their price target on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $173.56.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Principal Securities Inc. lifted its holdings in Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 59 shares during the period. Gladstone Institutional Advisory LLC increased its position in Natera by 1.7% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company’s stock worth $574,000 after buying an additional 61 shares in the last quarter. Silver Oak Securities Incorporated increased its position in Natera by 3.1% in the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company’s stock worth $470,000 after buying an additional 89 shares in the last quarter. Covestor Ltd increased its position in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares in the last quarter. Finally, Colonial Trust Co SC increased its position in Natera by 7.8% in the fourth quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company’s stock worth $210,000 after buying an additional 96 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.